Innate Pharma SA reported revenue and other income of €11.7 million in 2011, reflecting the impact of its licensing agreement with Bristol-Myers Squibb Company for rights to an anti-cancer monoclonal antibody in early clinical development. ---Subscribe to MedNous to access this article--- Company News
